Cancer is one of the top leading causes of mortality. According to WHO, over 8 million people die of cancer worldwide every year. While there have been important advances in therapeutic treatments in recent years, there is still a need for more innovative medicines to improve survival rates and life quality of patients. Our research is committed to discovering and developing therapies that work against the processes cancer cells need to survive.
NMT Pharma oncology pipeline includes CZ-48, an analogue of camptothecin which is currently in clinical trials. We continue to discover and develop other new analogues of the camptothecin family to improve its safety, efficacy as well as patient compliance. We also develop generic solutions to our customers as alternative to achieve their bioequivalent targets to innovative medicines.